Algernon Pharmaceuticals: Developing Drugs for Global Diseases
Algernon Pharmaceuticals is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) and …
Fast-tracking drugs into human trials
Algernon Pharmaceuticals is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) and chronic cough, and COVID-19.
The company and its business model are highly capital efficient and strive to deliver maximum shareholder value. Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several potential benefits over traditional drug development including a reduction in investment and risk, shorter research periods, and a longer active patent life.
The company enters into a clinical trial agreement with Yale University for a DMT phase 2 depression study.
For more information on Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
HIVE Digital Technologies: Building the Future with Bitcoin and AI
HIVE Digital Technologies (TSX.V: HIVE, NASDAQ: HIVE) isn’t just mining Bitcoin—it’s powering the next era of high-performance computing. With a strong focus on sustainability and AI infrastructure, HIVE is executing on two transformative trends at once.
